Go Pro
→ Are you signed up for this 4x text message? (From Weiss Ratings) (Ad)tc pixel Free ACB Stock Alerts

Aurora Cannabis (ACB) Competitors

Aurora Cannabis logo
C$5.04 -0.23 (-4.36%)
As of 12:51 PM Eastern
Compare

ACB vs. DHT.UN, THCX, GUD, TLRY, and CMED

Should you buy Aurora Cannabis stock or one of its competitors? Aurora Cannabis's main competitors and comparable companies include DRI Healthcare Trust (DHT.UN), Hydropothecary (THCX), Knight Therapeutics (GUD), Tilray Brands (TLRY), and CanniMed Therapeutics (CMED). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aurora Cannabis compare to DRI Healthcare Trust?

Aurora Cannabis (TSE:ACB) and DRI Healthcare Trust (TSE:DHT.UN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

In the previous week, DRI Healthcare Trust had 1 more articles in the media than Aurora Cannabis. MarketBeat recorded 5 mentions for DRI Healthcare Trust and 4 mentions for Aurora Cannabis. DRI Healthcare Trust's average media sentiment score of 1.12 beat Aurora Cannabis' score of 0.77 indicating that DRI Healthcare Trust is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
DRI Healthcare Trust
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

DRI Healthcare Trust has lower revenue, but higher earnings than Aurora Cannabis. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora CannabisC$314.07M0.99-C$44.16M-C$1.94N/A
DRI Healthcare TrustC$172.34M5.80C$9.73M-C$0.80N/A

Aurora Cannabis has a beta of 0.246838, meaning that its share price is 75% less volatile than the broader market. Comparatively, DRI Healthcare Trust has a beta of 0.350693, meaning that its share price is 65% less volatile than the broader market.

DRI Healthcare Trust has a net margin of 5.02% compared to Aurora Cannabis' net margin of -9.53%. DRI Healthcare Trust's return on equity of 2.06% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-9.53% -5.21% -1.87%
DRI Healthcare Trust 5.02%2.06%4.22%

Aurora Cannabis presently has a consensus target price of C$7.17, suggesting a potential upside of 42.20%. DRI Healthcare Trust has a consensus target price of C$25.20, suggesting a potential upside of 38.77%. Given Aurora Cannabis' higher possible upside, equities analysts clearly believe Aurora Cannabis is more favorable than DRI Healthcare Trust.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
DRI Healthcare Trust
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

4.2% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 0.8% of DRI Healthcare Trust shares are owned by institutional investors. 0.1% of DRI Healthcare Trust shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

DRI Healthcare Trust beats Aurora Cannabis on 13 of the 17 factors compared between the two stocks.

How does Aurora Cannabis compare to Hydropothecary?

Aurora Cannabis (TSE:ACB) and Hydropothecary (CVE:THCX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

4.2% of Aurora Cannabis shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Hydropothecary has a net margin of 0.00% compared to Aurora Cannabis' net margin of -9.53%. Hydropothecary's return on equity of 0.00% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-9.53% -5.21% -1.87%
Hydropothecary N/A N/A N/A

Hydropothecary has lower revenue, but higher earnings than Aurora Cannabis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora CannabisC$314.07M0.99-C$44.16M-C$1.94N/A
HydropothecaryN/AN/AN/AN/AN/A

In the previous week, Aurora Cannabis had 4 more articles in the media than Hydropothecary. MarketBeat recorded 4 mentions for Aurora Cannabis and 0 mentions for Hydropothecary. Aurora Cannabis' average media sentiment score of 0.77 beat Hydropothecary's score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company Overall Sentiment
Aurora Cannabis Positive
Hydropothecary Neutral

Aurora Cannabis currently has a consensus target price of C$7.17, suggesting a potential upside of 42.20%. Given Aurora Cannabis' stronger consensus rating and higher probable upside, equities research analysts plainly believe Aurora Cannabis is more favorable than Hydropothecary.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Hydropothecary
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Aurora Cannabis beats Hydropothecary on 7 of the 10 factors compared between the two stocks.

How does Aurora Cannabis compare to Knight Therapeutics?

Knight Therapeutics (TSE:GUD) and Aurora Cannabis (TSE:ACB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

22.8% of Knight Therapeutics shares are held by institutional investors. Comparatively, 4.2% of Aurora Cannabis shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Knight Therapeutics presently has a consensus target price of C$9.50, indicating a potential upside of 2.70%. Aurora Cannabis has a consensus target price of C$7.17, indicating a potential upside of 42.20%. Given Aurora Cannabis' higher probable upside, analysts plainly believe Aurora Cannabis is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aurora Cannabis
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Knight Therapeutics has higher revenue and earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$547.31M1.66-C$30.73MC$0.1561.67
Aurora CannabisC$314.07M0.99-C$44.16M-C$1.94N/A

Knight Therapeutics has a net margin of 2.72% compared to Aurora Cannabis' net margin of -9.53%. Knight Therapeutics' return on equity of 1.91% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Knight Therapeutics2.72% 1.91% 0.51%
Aurora Cannabis -9.53%-5.21%-1.87%

Knight Therapeutics has a beta of -0.194384, indicating that its stock price is 119% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.246838, indicating that its stock price is 75% less volatile than the broader market.

In the previous week, Aurora Cannabis had 3 more articles in the media than Knight Therapeutics. MarketBeat recorded 4 mentions for Aurora Cannabis and 1 mentions for Knight Therapeutics. Knight Therapeutics' average media sentiment score of 1.64 beat Aurora Cannabis' score of 0.77 indicating that Knight Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Knight Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Aurora Cannabis
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Knight Therapeutics beats Aurora Cannabis on 12 of the 16 factors compared between the two stocks.

How does Aurora Cannabis compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Aurora Cannabis (TSE:ACB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Tilray Brands has a beta of 2.949831, meaning that its stock price is 195% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.246838, meaning that its stock price is 75% less volatile than the broader market.

Aurora Cannabis has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray BrandsC$915.45M0.95-C$183.24M-C$1.09N/A
Aurora CannabisC$314.07M0.99-C$44.16M-C$1.94N/A

In the previous week, Aurora Cannabis had 2 more articles in the media than Tilray Brands. MarketBeat recorded 4 mentions for Aurora Cannabis and 2 mentions for Tilray Brands. Aurora Cannabis' average media sentiment score of 0.77 beat Tilray Brands' score of -0.09 indicating that Aurora Cannabis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tilray Brands
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aurora Cannabis
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

4.6% of Tilray Brands shares are held by institutional investors. Comparatively, 4.2% of Aurora Cannabis shares are held by institutional investors. 0.7% of Tilray Brands shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aurora Cannabis has a net margin of -9.53% compared to Tilray Brands' net margin of -15.22%. Aurora Cannabis' return on equity of -5.21% beat Tilray Brands' return on equity.

Company Net Margins Return on Equity Return on Assets
Tilray Brands-15.22% -8.85% -1.41%
Aurora Cannabis -9.53%-5.21%-1.87%

Tilray Brands presently has a consensus price target of C$13.30, indicating a potential upside of 109.12%. Aurora Cannabis has a consensus price target of C$7.17, indicating a potential upside of 42.20%. Given Tilray Brands' higher possible upside, analysts clearly believe Tilray Brands is more favorable than Aurora Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray Brands
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Aurora Cannabis
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Summary

Aurora Cannabis beats Tilray Brands on 9 of the 16 factors compared between the two stocks.

How does Aurora Cannabis compare to CanniMed Therapeutics?

Aurora Cannabis (TSE:ACB) and CanniMed Therapeutics (TSE:CMED) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

CanniMed Therapeutics has lower revenue, but higher earnings than Aurora Cannabis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora CannabisC$314.07M0.99-C$44.16M-C$1.94N/A
CanniMed TherapeuticsN/AN/AN/AN/AN/A

CanniMed Therapeutics has a net margin of 0.00% compared to Aurora Cannabis' net margin of -9.53%. CanniMed Therapeutics' return on equity of 0.00% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-9.53% -5.21% -1.87%
CanniMed Therapeutics N/A N/A N/A

In the previous week, Aurora Cannabis had 4 more articles in the media than CanniMed Therapeutics. MarketBeat recorded 4 mentions for Aurora Cannabis and 0 mentions for CanniMed Therapeutics. Aurora Cannabis' average media sentiment score of 0.77 beat CanniMed Therapeutics' score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company Overall Sentiment
Aurora Cannabis Positive
CanniMed Therapeutics Neutral

4.2% of Aurora Cannabis shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Aurora Cannabis presently has a consensus target price of C$7.17, indicating a potential upside of 42.20%. Given Aurora Cannabis' stronger consensus rating and higher possible upside, research analysts clearly believe Aurora Cannabis is more favorable than CanniMed Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
CanniMed Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Aurora Cannabis beats CanniMed Therapeutics on 7 of the 10 factors compared between the two stocks.

Get Aurora Cannabis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACB vs. The Competition

Export
MetricAurora CannabisPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$312.19MC$11.72BC$6.98BC$12.55B
Dividend YieldN/A2.70%2.58%6.20%
P/E Ratio-2.60781.44269.2730.74
Price / Sales0.99748.15597.319.76
Price / Cash1.2567.4570.5382.29
Price / Book0.5910.7713.074.64
Net Income-C$44.16MC$2.78BC$3.45BC$299.09M
7 Day Performance21.45%-0.17%0.74%0.92%
1 Month Performance34.04%0.00%1.40%3.90%
1 Year Performance-32.17%161.17%67.03%36.15%

Aurora Cannabis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACB
Aurora Cannabis
2.7902 of 5 stars		C$5.04
-4.4%		C$7.17
+42.2%		-30.9%C$312.19MC$314.07MN/A1,073
DHT.UN
DRI Healthcare Trust
3.3647 of 5 stars		C$18.66
+3.6%		C$25.20
+35.0%		+21.9%C$1.03BC$163.77MN/AN/A
THCX
Hydropothecary
N/AC$5.30
+6.6%		N/A+0.0%C$949.11MN/AN/AN/A
GUD
Knight Therapeutics
1.1298 of 5 stars		C$9.50
+2.0%		C$9.50
+45.0%C$933.20MC$510.45M158.33725
TLRY
Tilray Brands
1.3283 of 5 stars		C$6.62
+7.5%		C$13.30
+100.9%		-61.9%C$901.67MC$915.45MN/A2,650

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:ACB) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
BSEM Is Officially on Nasdaq... The Next Chapter Begins!
BioStem Technologies (NASDAQ: BSEM) debuted on Nasdaq August 7th, marking its move from OTC markets into a new...
Huge Alerts | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Buffett's Final Warning: "The Dollar Is Going to Hell"
The US just hit $39 trillion in debt. Interest alone is now over $1 trillion a year, more than the entire defe...
Decentralized Masters | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel